Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BLX 0631

X
Drug Profile

BLX 0631

Alternative Names: BLX-0631

Latest Information Update: 18 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biolexis Therapeutics
  • Class Antineoplastics
  • Mechanism of Action Proto oncogene proteins c pim 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Multiple myeloma; Renal cell carcinoma; Systemic lupus erythematosus

Most Recent Events

  • 18 Jan 2024 Biolexis Therapeutics plans to submit IND application for BLX 0631 in Q3 2024 (Biolexis Therapeutics pipeline, January 2024)
  • 18 Jan 2024 Biolexis Therapeutics plans a phase I trial for BLX 0631 in Q4 2024 (Biolexis Therapeutics pipeline, January 2024)
  • 27 Jun 2023 BLX 0631 is available for licensing as of 27 Jun 2023. https://www.bisichem.com/default/#vision
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top